Unmet Needs in the Management of Gastroesophageal Reflux Disease

Similar documents
GERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University

GERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018

ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease

Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors

Refractory GERD : case presentation and discussion

Refractory GERD. Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida

Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI

Disclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.

Burning Issues in Gastroesophageal Reflux Disease (GERD)

Hold the Wrap! There is so much more to be done!

NEGATIVE ENDOSCOPY, What is the Diagnosis and Treatment?

Gastroesophageal Reflux Disease (GERD)

Refractory GERD: What s a Gastroenterologist To Do?

Drug Class Review on Proton Pump Inhibitors

Committee Approval Date: October 14, 2014 Next Review Date: October 2015

Drug Class Monograph

Review article: management of mild and severe gastro-oesophageal reflux disease

Nexium 24HR Pharmacy Training

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study

GERD: A linical Clinical Clinical Update Objectives

In the Name of God. Refractory GERD

Relieving Frequent Heartburn Day Through Night

SASKATCHEWAN REGISTERED NURSES ASSOCIATION

GERD. From Clinician to Pharmacologist. Chien-Heng, Shen

Four-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy

OTC PPI Therapy in Frequent Heartburn

Page 1. Objectives. The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in Frequent Heartburn

Heartburn is a common symptom among adults in

Nexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.

Reflux of gastric contents, particularly acid, into the esophagus

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

Gastroesophageal Reflux Disease, Paraesophageal Hernias &

Index. Note: Page numbers of article titles are in boldface type.

Many patients with gastroesophageal reflux

Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease

Approach to Patients with Non-Cardiac Chest Pain

SELF CARE OF HEARTBURN

Optimizing Medical Therapy for Gastroesophageal Reflux Disease: State of the Art Philip O. Katz, MD


Alimentary Pharmacology & Therapeutics SUMMARY

Review article: pharmacology of esomeprazole and comparisons with omeprazole

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)

CYP2C19-Proton Pump Inhibitors

Novel Therapy in Gastroesophageal Reflux Disease (GERD)

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Review article: immediate-release proton-pump inhibitor therapy potential advantages

Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013

Drug Class Review Proton Pump Inhibitors

GERD: How to. Failures

SUMMARY INTRODUCTION. Accepted for publication 4 June 2004

GERD. Gastroesophageal reflux disease, or GERD, occurs when acid from the. stomach backs up into the esophagus. Normally, food travels from the

Maximizing Outcome of Extraesophageal Reflux Disease. (GERD) is often accompanied

GERD: Pitfalls and Pearls

Gastroesophageal Reflux Disease (GERD)

Heartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus.

Proton Pump Inhibitor Clinical Trials: Focus On Lansoprazole In The Treatment Of Gastroesophageal Reflux Disease And Frequent Heartburn

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

ACID REFLUX & GERD: The Unsettling Reality in Canada

Functional Heartburn and Dyspepsia

Gastroesophageal Reflux Disease (GERD)

TBURN TBURN BURN ARTBURN EARTBURN EART HEARTBURN: HOW TO GET IT OFF YOUR CHEST

Speaker disclosure. Objectives. GERD: Who and When to Treat 7/21/2015

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist

Gastro esophageal reflux disease DR. AMMAR I. ABDUL-LATIF

Laryngopharyngeal Reflux

David A. Peura 1,5*, Anne Le Moigne 2, Heather Wassel 3 and Charles Pollack 4

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

ORIGINAL ARTICLES ALIMENTARY TRACT. A Randomized, Comparative Study of Three Doses of AZD0865 and Esomeprazole for Healing of Reflux Esophagitis

Drug Class Review on Proton Pump Inhibitors

CMEARTICLE. WHAT CAN I DO IN MY PRACTICE? History. Daphne Ang 1, MBBS, FRCP (Edin), Choon How How 2, MMed, FCFP, Tiing Leong Ang 1, MBBS, FRCP (Edin)

Treatment of Nonerosive Reflux Disease (Beyond Proton Pump Inhibitors)

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis

Putting Chronic Heartburn On Ice

Number of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI

Disclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None

Nonerosive reflux disease as a presentation of gastro-oesophageal reflux disease

Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next?

Alginates Extended Abstract

July 19, Division of Dockets Management Food and Drug Administration 5630 Fishers Lane Room 1061, HFA-305 Rockville, Maryland 20852

Treatment Options for GERD or Acid Reflux Disease A Review of the Research for Adults

GASTROESOPHAGEAL REFLUX

QUICK QUERIES. Topical Questions, Sound Answers

Disclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome

ORIGINAL ARTICLES ALIMENTARY TRACT

How to Manage Refractory Heartburn

11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.

GASTROESOPHAGEAL reflux

Review article: treatment of mild and severe cases of GERD

Gastroesophageal reflux disease. The case for improving patient education in primary care

GASTROESOPHAGEAL REFLUX DISEASE. William M. Brady

Symptom Characteristics and Psychosomatic Profiles in Different Spectrum of Gastroesophageal Reflux Disease

Alternative Therapeutic Approaches to Chronic Proton Pump Inhibitor Treatment

GERD: Current Challenges in Control David Armstrong, MD McMaster University Hamilton, ON

ORIGINAL ARTICLE. Abstract. Introduction. Masaki Miyamoto 1, Noriaki Manabe 2 and Ken Haruma 2

You May Be at Risk. You are currently taking a proton pump inhibitor (PPI):

Review article: alternative approaches to the long-term management of GERD

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection

DYSPEPSIA Dyspepsia indigestion during or after eating Full Heat, burning or pain Note: one of every four people

Key Words Gastroesophageal reflux; Gastrointestinal motility; Proton pump inhibitors; Therapeutics

Transcription:

Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal and Swallowing Center MetroHealth Medical Center Cleveland, Ohio USA

Patients Report Attributes Extremely Important when Selecting Stomach Relief Medication Fast-acting relief (79%) Long lasting (67%) No side effects (60%) Effectively blocks symptoms (55%) Economical price (48%) One dose prevents breakthrough symptoms (48%) One dose lasts 12-24 hours (42%) Recommended by doctor (39%) Comes in a form I want (34%) Don t need prescription (32%) N = 1004 Gallup Organization. The 2000 Gallup Study of Consumers' Use of Stomach Relief Products.

What are the Areas of Unmet Need in GERD? Advance grading of erosive esophagitis (15-30% 20%) Dickman R et al J Neurogastroenterol Motil 2015 (in press)

Erosive Esophagitis Healing by Baseline LA Grade Omeprazole Esomeprazole Patients Healed (% 100 80 60 40 20 90.4 93.4 * * * 89.4 87.2 81.3 70.4 63.8 80 * 0 Grade A Grade B Grade C Grade D N=813 N=972 N=497 N=140 P<0.01 Cochran-Mantel-Haenszel. Richter et al. Am J Gastroenterol 2002 Week 8

Patients With Heartburn Symptoms, % Symptoms Persist in Some Erosive Esophagitis Patients Despite PPI Treatment Patients With Incomplete Symptom Relief After 8 Wks of PPI Therapy 50 45 40 35 30 25 20 15 10 5 0 Richter N=2425 2001 Kahrilas N=1960 2000 Castell N=5241 2002 Fennerty N=999 2005 Labenz N=2766 2005 Katz et al. Aliment Pharmacol Ther. 2006;23(suppl 2):9-22.

Endoscopically Confirmed Healing Rates of Refractory Reflux Esophagitis after 8 weeks of Treatment Kinoshita et al. Am J Gastroenterol 2012;107:522-30.

Kinoshita et al. Am J Gastroenterol 2012;107:522-30.

What are the Areas of Unmet Need in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Dickman R. et al J Neurogastroenterol Motil 2015 (in press)

Symptom Response Rate to Standard Dose PPI Therapy in Patients with NERD versus Patients with Erosive Esophagitis Standard-dose PPI Therapy Placebo Pooled symptomatic response rate at 4 weeks (%) 60 50 40 30 20 10 0 55.5 36.7 9.5 7.5 NERD (N=1854) Erosive esophagitis (N=705) *P<0.0001 compared with patients with NERD * Dean et al. Clin Gastroenterol Hepatol 204;2:656-664

Comparison of Response to Proton Pump Inhibitor Treatment Between NERD and Erosive Esophagitis Patients NERD Erosive esophagitis Lag time to sustained symptomatic relief 6 days 4 5 days Symptomatic response to standard versus half dose No difference Increase Fass R, J Clin Gastroenterol 2007; 41:131-=137

Treatment Comparison between Placebo and PPI Once Daily in NERD Patients (Pooled Difference in Proportion with Heartburn Resolution by Time) Dean et al. Clin Gastroenterol Hepatol 2004;2:656-664

Proportion of NERD Patients Responding to Treatment at 4 Weeks 80 60 Omeprazole 20mg Omeprazole 10mg Placebo 61 % patients 40 46 31 49 24 20 13 0 Complete absence of heartburn Resolution of heartburn Lind et al. Scand J Gastroenterol 1997 N = 509

Exclude Functional Reflux Hypersensitivity and Functional Heartburn Patient with heartburn Endoscopy Normal endoscopy ph testing 50% abnormal normal 50% Symptom index 37% Positive Negative 63% Responsive PPI treatment Not responsive Functional reflux hypersensitivity Functional heartburn

Esophageal Hypersensitivity Very Common in NERD Trimble KC et al. Gut 1995;37:7-12. Maradey Romero et al.cgh Esophageal Hypersensitivity The perception of nonpainful esophageal stimuli as being painful, and painful esophageal stimuli as more painful 86% of NERD

Pain Modulators: An Additional Treatment For NERD? Antidepressants TCA s, SSRIs,SNRIs and Trazodone Adenosin agonists Serotnin agonists Antiepileptics (theophylline) (tegaserod) (Pregabalin) Peripheral neuropathy analgesics (Gabapentin) Alternative and complimentary medicine Dickman R, Maradey-Romero C, Fass R. Neurogastroenterol and Motil 2014;26:603-10.

What are the Areas of Unmet Need in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

ph Postprandial Heartburn A Therapeutic Challenge 8 6 4 2 meal heartburn 0 16:00 17:00 18:00 19:00 Time (PM) Orr WC. Am J Med. 2003;115(Suppl 3A):S109-S113.

Potassium Competitive Acid Blockers (P-CAB) - Mean steady-state intragastric ph profiles on Day 7 With Vonoprazan (TAK-438) Jenkins R et al. Gut 2012 (Suppl.)

What are the Areas of Unmet Need in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Nighttime heartburn (50% 38%) Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

Breakthrough Nighttime Symptoms on PPI Once Daily During sleep 28 Breakthrough symptoms, 38% At night 65 No breakthrough symptoms, 62% Mid day 45 N=1064 In the morning 16 American Gastroenterology Association. GERD Patient Study: Patients and Their Medications. Harris Interactive Inc; 2008.

Percentage of Symptomatic GERD Patients with Relief of Nighttime Heartburn (Esomeprazole 20 mg for 4 weeks) 60 50 Patients with relief of nighttime heartburn % 40 30 20 10 * 34.3 10.4 0 Esomeprazole 20 mg (N=137) Johnson D et al. Aliment Pharmacol Ther 2010;32:182-190 Placebo (N=125) *P<0.0001 vs placebo

Therapeutic options for Nighttime GERD Avoid eating at least 3 hours prior bedtime Elevate the head of the bed Avoid the R decubitus position in bed Turn off lights when enter bed and minimize disturbances to a normal sleep Treat with a PPI and if symptoms are primarily during nighttime - give before dinner Split PPI dose (am and pm before a meal) Add H2RA, carafate, gaviscon etc. before bedtime Consider non-medical treatment Fujiwara Y et al. J Gastroenterol 2012:47:760-9.

The Effect of Dexlansoprazole MR on Nighttime GERD Symptoms and Sleep Disturbances Relief= 6 of 7nights w/ no HB, allows 1 night w/ mild HB; 6 of 7 nights w/ no GERDrelated sleep disturbance

Should We Consider Combined Treatment For GERD? Decrease Sleep Decrease Alter Esophageal physiology Increase Increase GERD Increase Schey et al. Gastroenterology 2007; 133:1787-1795

Ramelteon Consider for Nighttime GERD Non-Scheduled hypnotic A selective MT1 and MT2 agonist Pharmacological structure close to omeprazole ( crude omeprazole ) Reduce Acid secretion and improve sleep Lokesh Jha et al JCG 2015 (in press) Nighttime heartburn Daytime heartburn *p<0.05

What are the Areas of Unmet Need in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Nighttime heartburn (50% 38%) On-demand / intermittent Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

GERD A Symptom Driven Disease I have heartburn I will take my medication Fass et al. Aliment Pharmacol Ther 2005;22(2):79-94.

On Demand Usage In Clinical Practice Of those taking lansoprazole or omeprazole over 30 days, how many days were they actually taken? 100 80 Percent (%)) 60 40 20 15% 11% 5% 6% 8% 55% 0 1-3 days 4-6 days 7-9 days 10-12 days 13-29 days 30 days 2000 Gallup Study of Consumer Use of Heartburn Products, May 2000.

On-Demand / Intermittent Treatment for GERD Intermittent Therapy Physician driven Administration of short, predetermined courses of therapy when symptoms recur (1 or 2 weeks duration). On-demand Therapy Patient driven Consumption of medical therapy when and during periods that patients desire.

On-Demand Rabeprazole Therapy in Nonerosive Reflux Disease 50 40 5 4 4.6 Rab 10 mg (n = 279) 30 20 20 3 2 2.5 Placebo (n = 139) 10 6 1 0 Patient Discontinuation* (%) 0 Mean Weekly Antacid Consumption (n) *Due to inadequate heartburn control. P <0.00001; P <0.0011; all comparisons vs placebo. Bytzer P, et al. Aliment Pharmacol Ther. 2004;20:181 188.

Cost-effectiveness of Different Therapeutic Strategies Decision analysis i. Lifestyle modifications plus antacids ii. H2RA to endoscopy iii. Step-up iv. Step-down v. PPI on demand vi. PPI maintenance PPI on-demand more effective and less costly Gerson L et al. Am J Gastroenterol. 2000;95:395.

What are the Areas of Unmet Needs in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Nighttime heartburn (50% 38%) Maintenance treatment (30%) Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

Maintenance Treatment Relapse Rates of Esophagitis Are High The majority will relapse without maintenance PPI therapy 15%-23% of LA grade A/B patients relapse within 6 months on maintenance PPI therapy 24%-41% of LA grade C/D patients relapse within 6 months on maintenance PPI therapy Lauritsen et al. Aliment Pharmacol Ther. 2003;17:333-341.

What are the Areas of Unmet Needs in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Nighttime heartburn (50% 38%) Maintenance treatment (30%) On-demand / intermittent (80-90%) Refractory GERD (30-40%) Atypical manifestations of GERD (noncardiac chest pain) Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

What are the Areas of Unmet Needs in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Nighttime heartburn (50% 38%) Maintenance treatment (30%) On-demand / intermittent (80-90%) Refractory GERD (30-40%) Atypical manifestations of GERD (noncardiac chest pain) Extraesophageal manifestations of GERD Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

Comparative Trial Between Esomeprazole 40mg Twice Daily Versus Placebo In Patients With Laryngeal Manifestations Of GERD 4 months

Laryngeal Manifestations Of GERD Vs.

Functional Laryngeal/Pharyngeal Disorders Embrace Them! Chronic Cough Throat clearing Throat Burning Throat Pain The burning mouth syndrome Dickman R et al. Neurogastroenterol Motil 2014;26:603-10

What are the Areas of Unmet Needs in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Nighttime heartburn (50% 38%) Maintenance treatment (30%) On-demand / intermittent (80-90%) Refractory GERD (30-40%) Atypical manifestations of GERD (noncardiac chest pain) Extraesophageal manifestations of GERD PPIs Dependence on food for efficacy Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

Mean ph Level DEXILANT Can Be Taken Without Regard to Food Mean Intragastric ph Over Time on Day 3 While on Dexlansoprazole 90 mg Daily Fasting 30 min after high-fat breakfast 5 min before high-fat breakfast 30 min before high-fat breakfast Lee RD et al. Aliment Pharmacol Ther. 2009;29(8):824-833. Hours From Dosing

Potassium Channel Blockers Bind reversibly and K competatively to the ATPase ( plasma level cell drug level) Able to inhibit the proton pump without acid activation ( not meal dependent) Weak base that accumulates in the parietal cell canaliculus. Potency is increased as a function of the pk a Rapid onset of effect complete acid blockade within 30 min. of administration Good oral bio-availability Maradey Romero & Fass Curr Gastroenterol Rep 2014;16:390

What are the Areas of Unmet Needs in GERD? Advance grading of erosive esophagitis (15-30% 20%) Nonerosive reflux disease (70% 40%) Postprandial heartburn (OTC market) Nighttime heartburn (50% 38%) Maintenance treatment (30%) On-demand / intermittent (80-90%) Refractory GERD (30-40%) Atypical manifestations of GERD (noncardiac chest pain) Extraesophageal manifestations of GERD PPIs Dependence on food for efficacy Alternative approaches to chronic PPI treatment Dickman R et al. J Neurogastroenterol Motil 2015 (in press)

Alternative Therapeutic Approaches Medical to Chronic PPI Treatment H2 blockers Antacids/ Gaviscon / sucralfate Prokinetics Baclofen Pain modulators Non-Medical Lifestyle modifications Endoscopic treatment Anti-reflux surgery Linx Psychological interventions Acupuncture Fass R. Clin Gastroenterol Hepatol 2012;10:338-345

New Area Of Unmet Need In GERD Bariatric Surgery

Esophageal Stricture Post Band Ligation

Severe Erosive Esophagitis After Sleeve Gastrectomy

The End